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ARTICLE OPEN
Monoclonal antibodies block transmission of genetically
diverse Plasmodium falciparum strains to mosquitoes
Roos M. de Jong 1,11, Lisette Meerstein-Kessel 1,2,11, Dari F. Da3, Sandrine Nsango4,5, Joseph D. Challenger 6,
Marga van de Vegte-Bolmer1, Geert-Jan van Gemert1, Elias Duarte7, Noam Teyssier7, Robert W. Sauerwein1,10, Thomas S. Churcher6,
Roch K. Dabire3, Isabelle Morlais4,8, Emily Locke9, Martijn A. Huynen 2, Teun Bousema 1,12✉ and Matthijs M. Jore 1,12✉
Malaria parasite transmission to mosquitoes relies on the uptake of sexual stage parasites during a blood meal and subsequent
formation of oocysts on the mosquito midgut wall. Transmission-blocking vaccines (TBVs) and monoclonal antibodies (mAbs) target
sexual stage antigens to interrupt human-to-mosquito transmission and may form important tools for malaria elimination.
Although most epitopes of these antigens are considered highly conserved, little is known about the impact of natural genetic
diversity on the functional activity of transmission-blocking antibodies. Here we measured the efficacy of three mAbs against
leading TBV candidates (Pfs48/45, Pfs25 and Pfs230) in transmission assays with parasites from naturally infected donors compared
to their efficacy against the strain they were raised against (NF54). Transmission-reducing activity (TRA) was measured as reduction
in mean oocyst intensity. mAb 45.1 (α-Pfs48/45) and mAb 4B7 (α-Pfs25) reduced transmission of field parasites from almost all
donors with IC80 values similar to NF54. Sequencing of oocysts that survived high mAb concentrations did not suggest enrichment
of escape genotypes. mAb 2A2 (α-Pfs230) only reduced transmission of parasites from a minority of the donors, suggesting that it
targets a non-conserved epitope. Using six laboratory-adapted strains, we revealed that mutations in one Pfs230 domain correlate
with mAb gamete surface binding and functional TRA. Our findings demonstrate that, despite the conserved nature of sexual stage
antigens, minor sequence variation can significantly impact the efficacy of transmission-blocking mAbs. Since mAb 45.1 shows high
potency against genetically diverse strains, our findings support its further clinical development and may inform Pfs48/45 vaccine
design.
npj Vaccines (2021)6:101; https://doi.org/10.1038/s41541-021-00366-9
INTRODUCTION
Malaria, caused by the unicellular parasite Plasmodium spp.,
continues to cause high mortality and morbidity worldwide1.
Current tools, while demonstrating great impact, are considered
insufficient to eliminate malaria from most African regions2. One
tremendous challenge for malaria control and elimination is the
efficient spread of malaria to mosquitoes that starts with the
uptake of circulating sexual stage parasites, gametocytes, by the
mosquito vector during a blood meal on an infected individual. In
the mosquito midgut, gametocytes egress from the host red
blood cells and develop into gametes. Male gametocytes produce
up to eight motile microgametes upon exflagellation and female
gametocytes develop into one immotile macrogamete. Zygotes
are formed upon fertilization of a macrogamete by a micro-
gamete3,4. The zygote develops into a motile ookinete that is able
to traverse the midgut wall to establish an oocyst5. After
differentiation and replication inside the oocyst, parasites are
released as sporozoites that migrate to the salivary glands and
render the mosquito infectious.
Transmission-blocking vaccines (TBVs) aim to induce antibodies
that are taken up by the mosquito vector together with the
infectious blood meal containing gametocytes. In the mosquito
midgut, these antibodies bind to surface antigens on sexual stage
parasites and thereby interfere with sexual development. Three
sexual stage antigens are currently under clinical development
and are leading TBV candidates: Pfs48/45, Pfs230, and Pfs25.
Pfs48/45 and Pfs230 are expressed on the surface of gametes and
antibodies targeting these antigens prevent fertilization6–9. Anti-
bodies against Pfs25 target zygotes and ookinetes and prevent
oocyst formation6,8,9. Development of these vaccine candidates
has been hampered by challenges with recombinant protein
expression and replication of pre-clinical successes. The first
versions of Pfs25-based vaccines have been tested in both naive
healthy adults and in malaria-exposed individuals10–13. Recently,
Pfs230-based vaccines have also entered phase I studies (ref. 14
and clinicaltrials.gov: NCT02942277), as well as a vaccine targeting
Pfs48/45 (clinicaltrials.gov: NCT04862416).
While the development of a highly effective TBV formulation is
still challenging, a panel of potent monoclonal antibodies (mAbs)
targeting these antigens is readily available. These have been
isolated from immunized rodents and block development of
cultured parasites in in vitro standard membrane feeding assays
(SMFAs)15. These mAbs provide insight into protective epitopes
and as such may inform vaccine design and development16.
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In addition, passive immunization with mAbs can form an
alternative immunization strategy that conveys predictable high-
level protection. Fc modifications that extend the serum half-life of
immunoglobulin (IgGs)17 make it conceivable that efficacious
concentrations of mAbs can be sustained for periods that are
sufficiently long to support malaria elimination initiatives, contain
outbreaks or span seasonal peaks of transmission.
Given the genetic diversity of parasites in endemic settings,
cross-strain protection is crucial for the efficacy of both active and
passive immunization strategies. Asexual stage antigens in
particular are highly polymorphic and vaccines targeting these
antigens face challenges to induce cross-strain protection18. The
general consensus is that sexual stage antigens are well conserved
(Supplementary Fig. 1); natural genetic variation may thus have
limited impact on TBVs and antibody efficacy. Nevertheless,
genetic variation has been observed, especially in Pfs23019. Given
their increasing prominence in malaria vaccine development, it is
both timely and important to assess whether active and passive
immunization strategies are likely to encounter challenges due to
genetic diversity. Here we compared the efficacy of mAbs
targeting Pfs48/45, Pfs230 and Pfs25 in membrane feeding assays
against cultured parasite strains and parasites derived from
naturally infected gametocyte carriers in Cameroon and
Burkina Faso.
RESULTS
Three mAbs strongly reduce transmission of reference strain
NF54
Transmission-reducing activity (TRA) was determined by SMFA for
three potent mAbs: 45.1 (α-Pfs48/45)20, 2A2 (α-Pfs230)21,22, and
4B7 (α-Pfs25)23. mAbs 45.1 and 2A2 are the most potent
transmission-blocking mAbs described to date; 4B7 targets Pfs25
that currently forms the most advanced TBV. All mAbs were raised
against Plasmodium falciparum NF54. Cultured NF54 parasites
were mixed with serial dilutions of mAbs and fed to Anopheles
stephensi mosquitoes. Oocysts were counted and TRA was
calculated as the mean decrease in the number of oocysts per
mosquito compared to negative controls from the same experi-
ment24. In SMFA experiments, reductions in oocyst intensity
(rather than prevalence) are the most robust and informative read-
out25. All three mAbs showed high TRA against the homologous
strain NF54 (Fig. 1a–c). We fitted linear models to the TRA data and
estimated mAb concentrations needed to achieve 80% reduction
in mean oocyst intensity (IC80), a consensus minimum level of TRA
to warrant further pre-clinical development26. mAbs 45.1 and 2A2
reduced infection intensity in mosquitoes with an IC80 of 1.8 μg/
mL [95% credible intervals: 1.4, 2.2] and 1.9 μg/mL [1.2, 3.5]
respectively, while mAb 4B7 was approximately 16-fold less
potent (IC80= 30.7 μg/mL, [20.7, 48.9]).
Two mAbs reduce transmission in field settings
We then tested the efficacy of mAbs in direct membrane feeding
assay (DMFA) experiments with blood from naturally infected
gametocyte carriers in Cameroon and Burkina Faso. Compared to
SMFA, these DMFA experiments more closely resemble natural
transmission conditions as they cover variation in gametocyte
densities, genetically diverse strains and potentially multiclonal
infections. Gametocyte densities were determined for the donors
and ranged from 16 to 504 gametocytes/µL (Median: 52;
Supplementary Dataset 1). Gametocyte density and average
oocyst intensity in DMFA experiments with serum replacement
were positively correlated (Spearman’s rank correlation coefficient
= 0.67, p < 0.0001; Supplementary Fig. 2). Multiplicity of infection
(MOI) was determined by AMA1 sequencing for a subset of
donors; 12/13 donors carried multiple P. falciparum clones
(Supplementary Dataset 1). Sequencing of parasite clones was
not performed for blood isolates due to complexity of associating
genotypes present in the bloodstream in relation to transmission
potential27. Naturally acquired antibodies were removed by serum
replacement and mAbs were added in European control serum at
various concentrations before feeding to Anopheles coluzzii
mosquitoes. At 94 μg/mL, mAb 4B7 oocyst intensity was reduced
by >80% in 30/37 of donors and in all (45/45) of donors at 15 μg/
mL mAb 45.1. In contrast, at 15 μg/mL mAb 2A2 >80% reduction
was only achieved in a minority of the donors (2/9) (Fig. 2). Oocyst
prevalence (i.e. the proportion of mosquitoes that became
infected) was reduced by >80% after addition of 94 μg/mL mAb
4B7 for 11/37 of donors, for 39/45 donors with 15 μg/mL of mAb
45.1 and for 1/9 of donors with 15 μg/mL mAb 2A2 (Supplemen-
tary Fig. 3). We observed comparable IC80 values for SMFA and
DMFA experiments with mAb 4B7 (Fig. 1a, d) and 45.1 (Fig. 1b, e),
demonstrating that these two antibodies reduce transmission of
the reference strain and field strains equally well. However, for
mAb 2A2 there was a clear discrepancy between SMFA and DMFA;
while mAb 2A2 had an IC80 of 1.9 μg/mL in SMFA, it showed low
TRA at 15 μg/mL in DMFA for most donors with values ranging
from −207.5 to 100% (median 72%) (Fig. 1f). We therefore
suspected that many patient-derived blood samples contained
parasite strains that were not sensitive to mAb 2A2.
Genetic variation affects transmission-blocking efficacy of
Pfs230 mAb 2A2
To further investigate the impact of genetic variation on the
efficacy of mAb 2A2, SMFA experiments with several laboratory-
adapted parasite strains were performed. SMFAs with six P.
falciparum strains demonstrated variation in antibody efficacy of
mAb 2A2 (Fig. 3a) in line with the observed variation in the DMFA
(Fig. 1f). Transmission of the reference strain NF54 was effectively
blocked, while for NF135 and NF183 slightly higher concentrations
were needed to achieve >80% TRA (Fig. 3a). Strains NF175, NF176
and NF149 were not sensitive to mAb 2A2, even at the highest
antibody concentrations tested.
Binding experiments in which female gametes were incubated
with mAb 2A2 demonstrated a similar heterogeneity in antibody
binding to parasite strains (Fig. 3b and Supplementary Fig. 4).
Strong reactivity of the mAb with native protein on the gamete
surface of NF54 parasites was observed, even at a low concentra-
tion of 0.2 µg/mL (Supplementary Fig. 4). Reactivity with the
surface of NF135 and NF183 gametes was observed at 25 µg/mL
(Fig. 3b), but not at concentrations <1 µg/mL (Supplementary Fig.
4). Strikingly, no antibody reactivity was observed with strains
NF175, NF176 and NF149 (Fig. 3b). For the strains that showed
binding with mAb 2A2 at all tested concentrations, we did not
detect any non-specific signal with the secondary antibody
(Supplementary Fig. 4). Binding of mAb 2A2 is thus in line with
its TRA in SMFA. The observed differences in antibody binding
were not the result of variation in Pfs230 antigen abundance as
demonstrated by binding experiments with polyclonal anti-Pfs230
mice serum (Fig. 3b), suggesting that polymorphisms affect
binding and thereby cause differences in functional activity.
The Pfs230 domain that is targeted by mAb 2A2 is currently
unknown. In western blots, mAb 2A2 did not recognize
recombinantly expressed fusion of pro-domain and domain I,
while it did recognize Pfs230 in gametocyte extract (Supplemen-
tary Fig. 5). We explored Pfs230 sequence data to identify the
antibody-binding site. We had full genome sequences available
for three of the strains and full-length Pfs230 gene sequences
revealed five domains that contain unique non-synonymous
single-nucleotide polymorphisms (SNPs) for NF175 that are not
present in NF54 and NF135 (Supplementary Fig. 6). Sequencing of
these five domains in the other three strains suggested that
domain IV contains the presumed binding site of mAb 2A2, since
this is the only domain that contains non-synonymous SNPs in all
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three non-sensitive strains (NF149, NF175 and NF176) that are
absent in the sensitive strains (Fig. 3c and Supplementary Fig. 7).
One non-synonymous SNP, resulting in an H1159D mutation, is
unique to non-sensitive strains, suggesting that this residue could
be critical for antibody binding. However, other identified non-
synonymous SNPs may further affect binding, explaining the
lower antibody efficacy against NF135 and NF183 compared to
NF54. A three-dimensional (3D) model of domain IV revealed that
most of these non-synonymous SNP-encoded amino acids are in
close proximity to each other, and it is therefore plausible that
several are located in the mAb 2A2-binding site (Fig. 3d).
The amino acid variations that we find in Pfs230 domain IV in
the laboratory strains are also observed in parasite strains from
most geographical regions28 indicating that there is no geogra-
phical fixation (Supplementary Fig. 8). Analysis of all known non-
synonymous SNPs in Pfs230 as reported by PlasmoDB v46
demonstrates that domain IV is the most polymorphic region of
the protein (Supplementary Fig. 9). Altogether, our data strongly
suggest that domain IV is the binding domain of mAb 2A2 and
that amino acid mutations affect antibody binding and thereby
efficacy.
Frequency of non-synonymous SNPs is not associated with
antibody pressure
Based on variation in activity of mAb 2A2 in SMFA and DMFA, we
hypothesized that oocysts which formed despite high concentra-
tions of mAb were more likely to contain non-sensitive gene
variants. To test this hypothesis, we extracted DNA from single
oocysts that formed in mosquitoes that fed on gametocytes in the
SMFA DMFA
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Fig. 1 Comparison of transmission-reducing activity of monoclonal antibodies against laboratory-adapted and field strains. a–c Standard
membrane feeding assays (SMFAs) were performed with cultured P. falciparum NF54 parasites and A. stephensi mosquitoes. Monoclonal
antibodies (mAbs) 4B7 (Pfs25, a), 45.1 (Pfs48/45, b) and 2A2 (Pfs230, c) were added at the indicated concentrations to cultured NF54 parasites.
Thin grey lines connect observations from individual feeding experiments with multiple mAb concentrations. The green line represents the
overall fit from linear regression starting at the intercept (0% TRA at 0 μg/ml). Shaded area represents 95% credible intervals of the fit. mAb
concentrations that were not tested in direct membrane feeding assays are omitted from the overall fit (b, open circles). d–f Direct membrane
feeding assays (DMFAs) were carried out in Burkina Faso (red) and Cameroon (cyan). Thin grey lines connect observations from individual
patients. mAbs 4B7 (Pfs25, d), 45.1 (Pfs48/45, e) and 2A2 (Pfs230, f) were added at the indicated concentrations to venous blood samples. For
mAb 2A2 (Pfs230), DMFA was only carried out in Burkina Faso, with two concentrations per donor. The cyan and red line represent the overall
fit from linear regression starting at the intercept (0% TRA at 0 μg/ml). Shaded area represents 95% credible intervals of the fit. The mAb
concentration is shown on the x-axis (square root-transformed). The ratio of oocyst intensity in control conditions over antibody test
conditions is shown on the left y-axis and corresponding transmission-reducing activity (TRA) on the right y-axis. An oocyst ratio of 5 equals
80% TRA, which is indicated by a dashed horizontal line. Note that transmission in some conditions was higher compared to controls, i.e.
oocyst ratio <1. It is currently unclear whether this is a methodological artefact or real biological phenomenon related to low antibody
density38. Calculated IC80 values are shown in graphs, with 95% credible intervals shown between brackets. The raw data for DMFA and SMFA
experiments can be found in the Supplementary Material (Supplementary Dataset 1 and 2).
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presence of high mAb concentrations and sequenced the targeted
domains. These data were available for donors from Burkina Faso
only, where single oocyst dissections were performed. Oocyst
DNA was also sequenced from control samples without test
antibodies. We did not find non-synonymous SNPs in Pfs25 in
oocysts from both the antibody and control condition (Fig. 4a and
Supplementary Table 1).
Five non-synonymous SNPs have previously been reported in
the 6C domain of Pfs48/45, which is targeted by mAb 45.1
(PlasmoDB.org v4629). We detected three of these among the
sequenced oocysts (Fig. 4b and Supplementary Table 2). The most
frequent amino acid change (L314I), with a reported minor allele
frequency of 40%, was present in 13/14 oocysts isolated from
mosquitoes that received a blood meal with high mAb 45.1
concentrations and in 9/13 antibody control oocysts. All three
non-synonymous SNPs are distal to the previously characterized
binding site of mAb 45.1 and thus unlikely to affect binding
(Supplementary Fig. 10). A minority of oocysts contained the
NF54 sequence (1/14 high mAb oocysts and 3/13 antibody control
oocysts; Fig. 4b). For some donors, we sequenced multiple oocysts
and obtained more than one unique sequence, as could be
expected from multiclonal infections.
For Pfs230, we examined the sequence of domain IV, which we
identified as the likely target of mAb 2A2. No exact NF54 reference
sequence was observed. Two to eight non-synonymous SNPs
were detected in every oocyst examined (n= 15 for 15 μg/mL
mAb 2A2 and n= 16 for control; Fig. 4c; Supplementary Table 3).
At three positions (amino acid mutations H1180Y, Y1194S and
Q1250K), NF54 carries the minor allele while most oocysts and all
five analyzed laboratory-adapted strains carry the major allele
(Fig. 2c). The eight non-synonymous SNPs observed in the oocysts
were reported before and exact combinations of these SNPs for
each oocyst are diverse (Supplementary Table 3). Five oocysts
were identical to the NF135 genotype, but none of the other 31
oocysts matched with any of our laboratory strains. No clear
difference was observed in the number or combination of non-
synonymous SNPs in oocysts that appeared at high mAb 2A2
concentration compared to control condition.
DISCUSSION
One of the major hurdles in malaria vaccine and antibody
development is genetic variation across Plasmodium strains. Since
mAbs target single epitopes, they are particularly vulnerable to
polymorphisms. Although sexual stage antigens are more
conserved than asexual stage antigens, it is unknown whether
transmission-blocking antibodies indeed provide cross-strain
protection. In in vitro experiments with P. falciparum strains and
ex vivo assessments of mAb potency against naturally acquired
gametocytes, we demonstrate considerable variation in functional
activity between three potent transmission-blocking mAbs
that target antigens that are currently considered for vaccine
development.
mAbs are now increasingly considered as interventions for
malaria since potent human(ized) anti-Plasmodium mAbs are
available30,31 and mAbs are becoming affordable for use in low-
income settings32. mAbs that block transmission to mosquitoes
can be powerful tools to reduce transmission in areas aiming for
the elimination of (drug-resistant) malaria and areas characterized
by short seasonal malaria transmission. We evaluated the potency
of three established transmission-blocking mAbs against naturally
acquired P. falciparum strains in Cameroon and Burkina Faso and
compared to the potency against the strain they were raised
against (NF54). mAb 45.1 showed similar potency in field-based
DMFA compared to SMFA with NF54, demonstrating that it
efficiently blocks genetically diverse parasite strains and multi-
clonal infections. While the overall potency of mAb 45.1 was
similar, we sporadically observed oocysts at high mAb concentra-
tions in DMFA (Fig. 1b, e). Since many of our donors carried
multiclonal P. falciparum infections, introduction of the mAb could
potentially block sensitive clones but permit transmission of
concurrently present mutant clones. To test this hypothesis, we
sequenced the Pfs48/45-6C locus of single oocysts that appeared
at high concentrations of mAb 45.1 to determine whether these
are enriched for certain parasite genotypes as compared to
control feeds. Although the number of oocysts that were available
was too low for meaningful statistical comparisons, we observed
no clear enrichment of ‘escape’ variants (Fig. 4b). In total, we
identified three previously described SNPs33, all of which are
outside the mAb 45.1-binding site and thus unlikely to abrogate
binding (Supplementary Fig. 10). Moreover, at high mAb 45.1
concentration we identified one oocyst that had an identical
sequence of the 6C domain as NF54. Taken together, it seems
unlikely that parasites escape antibody pressure due to poly-
morphisms in the 6C domain. Small differences in achieving full
transmission blockade between DMFA and SMFA while having
highly comparable IC80 estimates have to be interpreted with
caution and may be a chance finding in the limited number of
individual experiments. The current data do not indicate
substantial heterogeneity in mAb efficacy. Similar findings were
obtained for mAb 4B7. Although this mAb had considerably lower
potency, it also blocked transmission of genetically diverse






















10 μg/mL 31 μg/mL 94 μg/mL
n=22 n=15 n=15 n=37
0.7 μg/mL 1.25 μg/mL 2.5 μg/mL 15 μg/mL









Fig. 2 Stratified transmission-reducing activity of three different monoclonal antibodies in direct membrane feeding assays on naturally
infected gametocyte carriers. The concentration of a monoclonal antibody (mAb) 4B7 (Pfs25), b mAb 45.1 (Pfs48/45) and (c) mAb 2A2
(Pfs230) in the feeder is indicated below bars. Transmission-reducing activity (TRA) was quantified as the reduction in mean oocyst intensity
between antibody control and mAb condition for each donor. Complete transmission-reducing (>99% TRA) is depicted in dark green and
strong reduction (80–99% TRA) in bright green. All donors with >1 oocyst/mosquito in antibody control condition (i.e. successful transmission)
were included and the number of distinct donor samples (n) tested for each antibody is given below bars. mAbs 4B7 and 45.1 were tested at
two sites (Burkina Faso and Cameroon) and mAb 2A2 was only tested in Burkina Faso. DMFA direct membrane feeding assays. The raw data for
DMFA and SMFA experiments can be found in the Supplementary Material (Supplementary Dataset 1 and 2).
R.M.de Jong et al.
4
npj Vaccines (2021) 101 Published in partnership with the Sealy Institute for Vaccine Sciences
Pfs25-targeting mAb34 and for sera from volunteers immunized
during a Pfs25/ISA51 phase 1 trial35.
In contrast, the Pfs230 targeting mAb 2A2 failed to block
transmission of gametocytes from most gametocyte donors
tested. While this was based on a limited number of experiments
and it is not possible to estimate what fraction of naturally
acquired infections was not blocked by 2A2, the limited mAb
efficacy is striking. This contrasts with its potency in the SMFA and
findings with polyclonal antibodies34,36 and strongly suggests that
genetic variation in the Pfs230 locus of circulating gametocytes
affects the efficacy of this mAb. Using six laboratory-adapted
strains from geographically distinct locations, we demonstrated
that mAb 2A2 did not bind to the gamete surface of certain strains
and that binding was in line with functional TRA. The target
epitope of mAb 2A2 is currently unknown. mAb 2A2 did not
recognize a properly folded recombinant protein that covers
domain I and the pro-domain (Supplementary Fig. 5); sequence
data from our six laboratory-adapted strains highlighted domain
IV of Pfs230, the domain with the highest SNP density of all Pfs230
domains (Supplementary Fig. 9), as plausible target.
Importantly, many immunogenicity studies with recombinant
Pfs230 fragments have demonstrated that only antibodies
induced against the pro-domain and domain I of Pfs230, which
together encompass the leading vaccine construct D1M37, block
transmission. Our data strongly suggest that another domain of
Pfs230 can also be the target of potent transmission-blocking
antibodies. Recombinant fragments covering domains outside the
pro-domain and domain I may have failed to induce efficacious
antibodies in previous studies due to improper folding of
recombinant immunogens. Our data support renewed efforts to
produce properly folded Pfs230 fragments, which could lead to
the discovery of potent novel Pfs230-based vaccine candidates.
In conclusion, we demonstrate that evaluating potency of
transmission-blocking mAbs against field strains is important in
the (pre-)clinical development process and for identification of
potent and conserved epitopes to inform vaccine design and
development. We tested three different mAbs against three
leading TB vaccine candidates and found that the potency of
one of these was affected by genetic diversity in contrast to the
other two mAbs. Increased oocyst densities were sporadically
observed in experiments with low mAb concentrations. Whether
this is explained by biologically relevant transmission enhance-
ment or methodological issues is currently unknown38 and
requires dedicated studies. Our data are not predictive for cross-
strain efficacy of other mAbs and polyclonal antibodies to these
targets as other antibodies may target different epitopes. Our
data suggest that mAb2A2 targets domain IV, which is the most
genetically diverse domain of Pfs230 (Supplementary Fig. 9). The
pro-domain and domain I contained in the leading Pfs230
vaccine construct (D1M) are more conserved and mAbs and
polyclonal antibodies against this target are therefore more
likely to provide cross-strain protection. Indeed, a potent human
Fig. 3 Transmission-reducing activity of monoclonal antibody 2A2 (Pfs230) is strain dependent. a Transmission-reducing activity (TRA) of
monoclonal antibody (mAb) 2A2 in standard membrane feeding assays with six laboratory-adapted parasite strains from different
geographical regions that were fed to A. stephensi mosquitoes. Lines represent the fitted linear models and shaded areas the 95% credible
intervals. IC80 values are shown with 95% credible intervals between brackets. For strains NF175 and NF176, no meaningful IC80 values of mAb
2A2 could be obtained due to very low efficacy. The raw data SMFA experiments can be found in the Supplementary Material (Supplementary
Dataset 2). b Female gamete surface immunofluorescent assay using laboratory-adapted parasite strains incubated with 25 µg/mL of mAb 2A2
or serum from mice that were immunized with a fragment of Pfs230 (Pro+I, amino acids 443–736). Note that NF176 was incubated with
125 µg/mL mAb 2A2 (indicated with red asterisk). White arrows in bright field images indicate activated female gametes. Scale bars represent
10 µm. c Amino acid sequence alignment of Pfs230 domain IV (amino acids 1134–1268) of laboratory-adapted parasite strains. Non-
synonymous single-nucleotide polymorphism (SNP)-encoded amino acids are specified and invariant amino acids are shown as dots.
d Surface model of Pfs230 domain IV, based on the crystal structure of Pf41 (Pf3D7_0404900; PDB id: 4YS4), highlighting amino acids that vary
among the tested strains. Histidine 1159 (H1159) is mutated to aspartate in all strains that are not sensitive to mAb 2A2 and is highlighted in
red. Other amino acid variants are shown in blue. Histidine 1180 (H1180) is located in a non-structured loop, which is presented as a
dashed line.
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mAb (LMIV230-01) identified in immunized volunteers recog-
nizes and fixes complement on geographically distinct strains39
and Pfs230D1M-based vaccines show great promise14. The most
potent human mAbs against Pfs230 and Pfs25 are LMIV230-01
(IC80= 10–60 µg/mL) and mAb2544 (IC80= 16 µg/mL)40 and
more potent mAbs may be discovered in the future.
Importantly, mAb 45.1 is the most potent transmission-blocking
mAb described to date and shows potent cross-strain protection
in our DMFA experiments. A fully humanized version of mAb 45.1,
TB31F30, is currently being tested in a phase I experimental
medicine study (clinicaltrials.gov: NCT04238689). Based on our
equivalent SMFA and DMFA data for mAb 45.1, it can be assumed
that SMFA data obtained from this clinical trial will be predictive
for efficacy in field settings. Importantly, our data show that mAb
45.1 targets a conserved protective epitope, which may be used in
the design of Pfs48/45-based vaccines to specifically induce
antibodies against this epitope. Potent human mAbs may be
obtained from scheduled phase I vaccination trials with Pfs48/45.
Here we provide a framework for testing these newly identified
mAbs against genetically diverse parasites to further inform
design of this leading TBV candidate.
METHODS
mAb production
The generation of the mAbs against Pfs48/4520, Pfs23021,22 and
Pfs2523 have been described previously. Briefly, Pfs230 mAb
2A2.2a has been derived from mice immunized with P. falciparum
NF54 gametocyte extracts and underwent isotype switch to IgG2a
as described previously21,22. The Pfs48/45 targeting mAb 85RF45.1
(IgG1) has been derived from rats immunized with NF54
gametocyte extracts20. Pfs25 mAb 4B7 (IgG1) has been derived
from mice immunized with recombinant vaccinia virus expressing
Pfs2523. mAb 45.1 and 2A2 antibodies were affinity purified from
clarified hybridoma supernatant using MabSelect Xtra™ and
HiTrap Protein G columns (GE Healthcare Life Sciences), respec-
tively. Elution fractions containing the IgGs were dialysed against
phosphate-buffered saline (PBS), concentrated and freeze-dried
for storage. They were dissolved in distilled water before use. mAb
4B7 was a kind gift from PATH Malaria Vaccine Initiative.
Laboratory-adapted parasite strains and culture
P. falciparum strains were isolated from malaria patients and were
adapted to culture as described previously41. Briefly, parasites
were cultured in RPMI1640 medium supplemented with 10%
human serum at 5% haematocrit in a semiautomated suspension
culture system and cloned by limited dilution. The West-African
NF5442, Cambodian NF135.C1043 and Nigerian NF175.D544 para-
site strains have been described previously and compared at the
genome level45. Furthermore, NF149.A3 (Southern-Asia), NF176.B8
(East-Africa) and NF183.F7 (West-Africa) were used in this study46.
The clonality and identity of parasite strains was confirmed using
polymerase chain reaction (PCR) on glutamate-rich protein and
merozoite surface proteins 1 and 2 (MSP1 and MSP2) as described
previously47.
Standard membrane feeding assay
SMFAs were performed as described previously48. In brief, A.
stephensi mosquitoes from a colony maintained at Radboudumc
(Nijmegen, NL) were fed with P. falciparum mature gametocyte
cultures (days 15–17) mixed with human serum and active human
complement. mAbs were added to the gametocytes to achieve
the indicated final concentrations in the offered blood meals.
Mosquito midguts from a minimum of 20 mosquitoes per
condition were dissected, stained with mercurochrome and
checked for the presence of oocysts 6–8 days after the
blood meal.
Naturally infected gametocyte donors
Asymptomatic gametocyte carriers, aged 5–15 years, were
enrolled in Mfoe district (Cameroon) and Bobo Dioulasso (Burkina
Faso). Venous blood samples of 29 donors in Cameroon and 30
donors in Burkina Faso were collected after written informed
consent was obtained from participants or their guardian(s).
Ethical approval was provided by the National Ethics Committee
of Cameroon; Ethical Review Committee of the Ministry of Health,
Burkina Faso; Institutional ethics review committee for health
science research Bobo Dioulasso; University of California, San
Francisco; and London School of Hygiene and Tropical Medicine.
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Fig. 4 Genotypes of single oocysts that formed in the presence of high concentrations of monoclonal antibodies. Oocyst genotypes from
direct membrane feeding experiments with high concentrations of mAb 4B7 (Pfs25), mAb 45.1 (Pfs48/45) and mAb 2A2 (Pfs230) and from a
control condition without mAb were determined. The sequences were compared to the NF54 reference strain to identify non-synonymous
single-nucleotide polymorphisms (SNPs). Regions that were analyzed were full-length Pfs25 (a), 6C domain of Pfs48/45 (b) and domain IV of
Pfs230 (c). Only oocysts from Burkina Faso were available and included in this analysis. Single oocysts were not available for all donors or
conditions, the ‘n’ represents the number of oocysts analysed per condition with the number of donors in brackets. The raw data of this figure
can be found in the Supplementary Material (Supplementary Tables 2–4). *SNPs L314I and V304D; **SNPs L314I, V304D and S322N.
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Direct membrane feeding assay
Patient blood containing gametocytes was collected in heparin
tubes. Per tested condition, 500 µL of heparinized blood was
centrifuged (5 min at 2000 × g) and plasma was removed, then
replaced by 250 µL naive serum (=antibody control) or by naive
serum pre-mixed with mAb, achieving the final concentrations of
mAb in the total 500 µL volume. DMFA experiments that included
testing of mAb 2A2 were done with normal human serum, which
contains active complement, from naive European donors. In each
DMFA experiment, at least two mAbs were tested in parallel.
Minifeeders were filled with the mixture and A. coluzziimosquitoes
from local mosquito colonies were allowed to feed for 20min. All
materials were kept at 37 °C during the experiment. Fully fed
mosquitoes were kept 6–8 days post feeding; unfed and partially
fed mosquitoes were removed and not included in the analyses.
Approximately 20–30 mosquitoes were dissected for each
condition, midguts were stained with mercurochrome and oocysts
were counted. During dissection, infected midguts were collected
and stored in absolute ethanol at −80 °C. Subsequently, a
selection of midguts was gradually rehydrated in distilled water
and single oocysts were isolated according to the method
described by Annan et al.50. These single oocyst dissections were
performed in Burkina Faso only. The single oocysts were stored in
RNAprotect (Qiagen®, Hilden, Germany) at −80 °C.
Surface immunofluorescent assay (SIFA)
Cultured gametocytes (days 15–17) were activated by incubation
in foetal calf serum (FCS) for 1 h at room temperature. Cells that
include gametes were washed with PBS and incubated with mAb
2A2 dilutions in SIFA buffer (PBS/0.5% FCS/0.05% sodium azide).
The presence of Pfs230 on gamete surfaces was confirmed by
incubation with 1:20 dilution of serum from mice immunized with
Pfs230 fragment Pro+I (amino acids 443–736)51. Gamete prepara-
tions were washed three times with SIFA buffer and incubated
with 1:200 Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L)
(Invitrogen, Cat. No. A11001) at a 1:200 dilution in SIFA buffer.
All incubation steps were performed on ice for 1 h. For each
antibody concentration, three individual gametes were imaged
and representative pictures are shown.
Pfs230 domain IV model
The sequence of domain IV (amino acids E1134–D1268) was used
to generate a 3D model using the Fold & Function Assignment
Server (FFAS) of the Godzik laboratory52. The best hit in the PDB
database (PDB1018) was Pf41 (Pf3D7_0404900; PDB id: 4YS4).
Based on the alignment of the two sequences and the structure of
Pf41, a model was generated using default settings (SCWRL
modelling method and All-atom model type). Figures were
generated with PyMOL (Molecular Graphics System Version 2.3
Schrödinger, LLC).
Target antigen sequencing
DNA from single oocysts was isolated using phenolchloroform
(PC) extraction, following a slightly modified protocol published
by Ranford-Cartwright et al.53. In brief, the oocyst and surrounding
mosquito midgut material were digested overnight at 56 °C in
oocyst lysis buffer containing proteinase K. PC extraction was
followed by isopropanol precipitation and the obtained pellet was
washed with 70% ethanol, dried and dissolved in 20 μL H2O. The
target sequences were amplified from the obtained genomic DNA
by nested or semi-nested PCRs. In some cases, mixed signals were
obtained. These were either caused by the presence of multiple
oocysts or single oocysts that were a product of a male and female
gamete with different genotypes. These mixed oocysts were
counted as non-synonymous SNPs.
For sequence analysis of Pfs230 from cultured parasite strains,
genomic DNA was isolated from mixed parasite cultures using the
QIAamp® DNA Blood Mini Kit (Qiagen®, Hilden, Germany). The
Pfs230 gene (domains I–XIV) was amplified by PCR using
PrimeSTAR GXL DNA Polymerase (TaKaRa Bio, Shiga, Japan)
according to the manufacturer’s instructions. Domains that were
sequenced were selected based on the observed phenotypes of
NF54, NF135 and NF175 in the SMFA and the previously available
sequence data of these strains (Supplementary Fig. 6). Mutations
were confirmed in duplicate PCR reactions and two independent
sequencing reads per PCR reaction.
Sanger sequencing was performed at BaseClear (Leiden, the
Netherlands), and data were analyzed using Chromas Lite (Version
2.1.1, Technelysium Pty., Australia). Primers for amplification and
sequencing are listed Supplementary Table 4.
In silico sequence variation analysis
The available Pfs230 (PF3D7_0209000) protein sequences were
downloaded from PlasmoDB29. The domain composition as
defined in Gerloff et al.54 was used to calculate the density of
polymorphisms per region. For the distribution of the polymorph-
isms in domain IV over various regions, we used version 6 of the
MalariaGEN P. falciparum Community Project that contains VCF
files of 7113 sequenced strains28. Per strain, we included the most
frequently detected variant. Nucleotide changes were translated
into proteins and the sequence variation per region was visualized
using the sequence logo generator WebLogo version 2.8.255 after
performing a multiple sequence alignment using Clustal Omega56.
Multiplicity of infection
Parasite material (total nucleic acids isolated from whole blood)
from study participants was analyzed by amplicon deep sequen-
cing of apical membrane antigen 1 (AMA-1). Haemi-nested PCR
was used to amplify a 236 base-pair segment of AMA-1 using a
published protocol57. Samples were amplified in duplicate,
indexed, pooled and purified by bead cleaning. Sequencing was
performed on an Illumina MiSeq platform (150 bp paired-end).
Data extraction, processing and haplotype clustering were
performed using SeekDeep58. MOI was calculated as the number
of haplotypes present in both replicates of a given sample.
Statistical analysis of the membrane feeding assay data
TRA was quantified as the relative reduction in oocyst intensity
(mean oocyst count per dissected mosquito) when using mAbs
compared to the serum replacement (no antibody control) condition.
We quantified transmission reduction as suggested by Miura et al.24.
We fitted linear models to the TRA data by modelling the relationship
between the (log transformed) ratio of the oocyst counts observed in
the control and test arms and the (square root transformed) mAb
concentration. When oocysts with added mAb are completely absent
or at least 200-fold lower than that in the control, we assumed a
1:200 ratio (99.5% TRA). As we assumed zero TRA (i.e. an oocyst ratio
of one) in the absence of antibodies, we did not allow the intercept
of the regression models to vary when fitting the models. For each
antibody, we began with the simplest model possible, using the
same slope for the DMFA and SMFA data. No model was fit for the
DMFA data of 2A2, because of the heterogeneity of the results. We
then developed more complicated models and examined whether
the model fit improved. Using weakly informative priors, we allowed
the slopes to vary for the assay used and, for the DMFA data, the
country from which parasites were collected. We also included a
random effect in the slope for either the donor (DMFA data) or the
experiment (SMFA data). The regression modelling was carried out
using RStan (package version 2.21.1)59 and rethinking (package
version 2.01)60, and the goodness of fit was assessed via the widely
applicable information criterion61. For mAb 45.1, allowing the slopes
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to vary by assay and country slightly improved the goodness of fit.
For mAb 4B7, the more complicated models did not outperform the
simpler model (the same average slope for all the data). For the
results shown in Fig. 1, we present model predictions from an
ensemble of models, generated using the Akaike weight associated
with each model61. In the case of mAb 4B7, for example, the models
for the DMFA data from Burkina Faso and Cameroon are nearly
identical, as not much weight was attributed to models that
contained the country-specific term. For mAb 45.1, the country-
specific differences are more apparent but still quite small. All models
and respective goodness of fit are summarized in Supplementary
Table 5. The slopes of the regression models fitted to the SMFA data
of mAb 2A2 against the laboratory-adapted strains are provided in
Supplementary Table 6. SMFA and DMFA feeds were excluded from
the analysis for TRA if control mosquitoes had on average <1 oocyst/
mosquito or <30% of mosquitoes became infected, with the
exception of SMFA data for NF149 since transmission of this line is
in general less efficient. The raw data for DMFA and SMFA
experiments can be found in the Supplementary Material (Supple-
mentary Dataset 1 and 2).
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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